ArticleJournal of pharmaceutical policy and practice2026

Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis.

Shereen Elazzazy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.